Ajanta Pharma Ltd
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
- Market Cap ₹ 26,798 Cr.
- Current Price ₹ 2,134
- High / Low ₹ 2,355 / 1,241
- Stock P/E 36.4
- Book Value ₹ 277
- Dividend Yield 1.69 %
- ROCE 22.6 %
- ROE 17.9 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 117 days to 83.3 days
Cons
- Stock is trading at 7.72 times its book value
- The company has delivered a poor sales growth of 12.0% over past five years.
- Promoter holding has decreased over last 3 years: -4.13%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
677 | 931 | 1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,036 | |
545 | 706 | 840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,011 | |
Operating Profit | 132 | 224 | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,025 |
OPM % | 19% | 24% | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 25% |
6 | 6 | 14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 104 | |
Interest | 15 | 19 | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 |
Depreciation | 32 | 34 | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 134 |
Profit before tax | 91 | 177 | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 988 |
Tax % | 15% | 37% | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | |
77 | 112 | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 736 | |
EPS in Rs | 5.85 | 8.49 | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 58.26 |
Dividend Payout % | 11% | 13% | 15% | 17% | 17% | 23% | -0% | 20% | 24% | 13% | 11% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 12% |
3 Years: | 13% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 5% |
3 Years: | 8% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 26% |
3 Years: | 22% |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | 25% |
5 Years: | 20% |
3 Years: | 21% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 |
Reserves | 286 | 382 | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,457 |
200 | 125 | 130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 33 | |
151 | 200 | 226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 918 | |
Total Liabilities | 649 | 718 | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,433 |
246 | 273 | 279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,485 | |
CWIP | 3 | 12 | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 205 |
Investments | 8 | 8 | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 238 |
392 | 425 | 513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,506 | |
Total Assets | 649 | 718 | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,433 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
70 | 234 | 212 | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | |
-53 | -104 | -188 | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | -560 | |
-13 | -104 | -20 | -105 | -117 | -202 | -0 | -147 | -129 | -318 | -460 | -108 | |
Net Cash Flow | 4 | 26 | 4 | 16 | -0 | 24 | 25 | 4 | 104 | -24 | 28 | 124 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 76 | 59 | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 |
Inventory Days | 266 | 178 | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 |
Days Payable | 161 | 159 | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 |
Cash Conversion Cycle | 182 | 78 | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 |
Working Capital Days | 93 | 59 | 57 | 61 | 90 | 65 | 103 | 119 | 116 | 127 | 141 | 83 |
ROCE % | 23% | 39% | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Schedule of Earnings Conference Call to be held on 2nd May 2024, post Board meeting.
- Board Meeting Intimation for Board Meeting Scheduled To Be Held On Thursday 2Nd May 2024 To Consider And Approve Audited Financial Results (Consolidated & Standalone) For The Quarter And Year Ended 31St March 2024. 2d
-
Compliance With Reg. 40(10) Of The Listing Regulations - Compliance Certificate
18 Apr - PFA herewith Compliance Certificate under Regulation 40(10) of the SEBI (LODR) Regulations, 2015 from a PCS for the year ended 31st March 2024.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 15 Apr
- Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Period Ended 31St March 2024. 15 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Jan 2024TranscriptNotesPPT REC
-
Oct 2023TranscriptPPTREC
-
Jul 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Aug 2022TranscriptPPT
-
Jan 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
Apr 2021TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Apr 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Oct 2018TranscriptNotesPPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Oct 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Oct 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Apr 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]